Despite major advances in antiretroviral therapy, current therapies fail to meet the needs of many people living with HIV. The development of long-acting injectable anti-HIV therapy will offer more treatment options and, for some, may dramatically improve their quality of life. Now that Cabenuva is approved in Canada, the interest in switching to injectable therapy is becoming more apparent. While many challenges have been identified in the implementation of prescribing Cabenuva in clinical practice, a patient support program has been developed to help address many of these. While coverage by payors is still limited, early experience has been encouraging and informative.